| Literature DB >> 24625684 |
Pei Ching Low1, Silvia Manzanero2, Nika Mohannak3, Vinod K Narayana3, Tam H Nguyen3, David Kvaskoff3, Faith H Brennan4, Marc J Ruitenberg5, Mathias Gelderblom6, Tim Magnus6, Hyun Ah Kim7, Brad R S Broughton7, Christopher G Sobey7, Bart Vanhaesebroeck8, Jennifer L Stow9, Thiruma V Arumugam2, Frédéric A Meunier3.
Abstract
Stroke is a major cause of death worldwide and the leading cause of permanent disability. Although reperfusion is currently used as treatment, the restoration of blood flow following ischaemia elicits a profound inflammatory response mediated by proinflammatory cytokines such as tumour necrosis factor (TNF), exacerbating tissue damage and worsening the outcomes for stroke patients. Phosphoinositide 3-kinase delta (PI3Kδ) controls intracellular TNF trafficking in macrophages and therefore represents a prospective target to limit neuroinflammation. Here we show that PI3Kδ inhibition confers protection in ischaemia/reperfusion models of stroke. In vitro, restoration of glucose supply following an episode of glucose deprivation potentiates TNF secretion from primary microglia-an effect that is sensitive to PI3Kδ inhibition. In vivo, transient middle cerebral artery occlusion and reperfusion in kinase-dead PI3Kδ (p110δ(D910A/D910A)) or wild-type mice pre- or post-treated with the PI3Kδ inhibitor CAL-101, leads to reduced TNF levels, decreased leukocyte infiltration, reduced infarct size and improved functional outcome. These data identify PI3Kδ as a potential therapeutic target in ischaemic stroke.Entities:
Mesh:
Substances:
Year: 2014 PMID: 24625684 DOI: 10.1038/ncomms4450
Source DB: PubMed Journal: Nat Commun ISSN: 2041-1723 Impact factor: 14.919